1. Home
  2. RDW vs XERS Comparison

RDW vs XERS Comparison

Compare RDW & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redwire Corporation

RDW

Redwire Corporation

N/A

Current Price

$8.98

Market Cap

2.1B

Sector

Industrials

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$10.40

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDW
XERS
Founded
2020
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
RDW
XERS
Price
$8.98
$10.40
Analyst Decision
Buy
Strong Buy
Analyst Count
11
7
Target Price
★ $14.28
$12.86
AVG Volume (30 Days)
★ 9.4M
2.5M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
2.98
★ 100.00
EPS
N/A
★ N/A
Revenue
★ $335,381,000.00
$49,590,000.00
Revenue This Year
$41.71
$32.91
Revenue Next Year
$18.75
$23.75
P/E Ratio
N/A
★ N/A
Revenue Growth
10.29
★ 142.67
52 Week Low
$4.87
$5.25
52 Week High
$26.64
$11.42

Technical Indicators

Market Signals
Indicator
RDW
XERS
Relative Strength Index (RSI) 43.71 56.97
Support Level $8.39 $9.73
Resistance Level $10.43 $10.60
Average True Range (ATR) 0.53 0.48
MACD -0.01 -0.06
Stochastic Oscillator 47.40 41.25

Price Performance

Historical Comparison
RDW
XERS

About RDW Redwire Corporation

Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: